Trastuzumab: is the new evidence revolutionary?
Artigo
em Inglês
| IMSEAR
| ID: sea-111421
ABSTRACT
A few years back, the survival benefit of trastuzumab in HER 2 positive breast cancer patients presenting with metastatic disease was proven in a randomized setting. Recently a number of randomized trials have reported their results in the adjuvant setting in HER 2 positive patients. These trials have been considered by some as a landmark in the evolution of breast cancer management. Although the data is encouraging, it need to be seen in a proper perspective keeping in mind the limitations and the side effects reported. This article stresses the use of Herceptin in carcinoma breast patients in adjuvant setting with a cautionary eye.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Neoplasias da Mama
/
Feminino
/
Humanos
/
Ensaios Clínicos Controlados Aleatórios como Assunto
/
Quimioterapia Adjuvante
/
Receptor ErbB-2
/
Anticorpos Monoclonais
/
Antineoplásicos
Tipo de estudo:
Ensaio Clínico Controlado
Idioma:
Inglês
Ano de publicação:
2006
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS